Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
Business Wire India Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide…